Type I IFN immunoprofiling in COVID-19 patients

The Journal of allergy and clinical immunology

Trouillet-Assant S, Viel S, Gaymard A, Pons S, Richard JC, Perret M, Villard M, Brengel-Pesce K, Lina B, Mezidi M, Bitker L and Belot A

J Allergy Clin Immunol. 2020 Apr 29. pii: S0091-6749(20)30578-9

DOI: https:// doi.org/10.1016/j.jaci.2020.04.029.


COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-α2 production with about 20% of critically-ill patients unable to produce IFN-α2, highlighting the immune response heterogeneity and opening avenues for targeted therapies.

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more